Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Fiche publication
Date publication
janvier 2018
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine
Tous les auteurs :
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M
Lien Pubmed
Résumé
Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).
Mots clés
Adult, Aged, C-Reactive Protein, metabolism, Cohort Studies, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, blood, Ovarian Neoplasms, blood, Prognosis, Prospective Studies, ROC Curve, Reproducibility of Results, Serum Albumin, metabolism, Severity of Illness Index
Référence
Gynecol. Oncol.. 2018 01;148(1):36-41